To support more sensitive next-generation RDT development and screen asymptomatic malaria, we developed and evaluated the Q-PlexTM Human Malaria Array (Quansys Biosciences, Logan, UT), which quantifies the antigens commonly used in RDTs—Plasmodium falciparum–specific histidine-rich protein 2 (HRP2), P. falciparum-specific lactate dehydrogenase (Pf LDH), Plasmodium vivax–specific LDH (Pv LDH), and Pan malaria lactate dehydrogenase (Pan LDH), and human C-reactive protein (CRP), a biomarker of severity in malaria. This evidence concerns the gene CRP and malaria.